|Bid||456.96 x 800|
|Ask||463.86 x 1100|
|Day's range||450.98 - 458.10|
|52-week range||331.75 - 476.35|
|Beta (5Y monthly)||0.54|
|PE ratio (TTM)||18.11|
|Earnings date||30 Jan 2024 - 05 Feb 2024|
|Forward dividend & yield||2.48 (0.54%)|
|Ex-dividend date||30 Nov 2023|
|1y target est||499.33|
Bigtime medical distributors like McKesson (NYSE: MCK) and Cencora (NYSE: COR) make money by moving drugs and supplies to clinics and pharmacies worldwide. If you guessed Ozempic, the medication made by Novo Nordisk for type 2 diabetes, you're correct. Along with the drug's other formulations called Wegovy and Rybelsus, which are indicated for helping people to lose weight, Ozempic belongs to a class of medications called GLP-1 agonists.
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.